Trial NCT02710396

View at ClinicalTrials.gov 
Org. Study IDs: AAAQ5450
Secondary IDs: 1U54CA209997 R01CA205426

Last trial update was posted on 2023-07-24

MeSH Interventions

Carboplatin Paclitaxel Pembrolizumab Pemetrexed

MeSH Conditions

Carcinoma Carcinoma, Non-Small-Cell Lung

Other Conditions


Stopping Reasons

Frontline pembrolizumab approved in NSCLC as monotherapy and in combination with chemotherapy representing a new standard of care.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID